Disorders of the

lated cannabinoid receptors; (iv) selectively targeting nervous system as a whole, account for more hospitaliz-
cannabinoid CB2 receptors; and/or (v) adjunctive ations, more long-term care and more chronic suffering
‘multi-targeting’. Minimizing the adverse effects of | than nearly all other disorders combined. What still
cannabinoid receptor agonists in the clinic requires remains a fact is that previous years have shown a
careful consideration of the likely strengths and weak- marked improvement in the treatment of various neuro-
nesses for improving the therapeutic efficacy and/or logical conditions thanks to the vast advancements in
limiting the adverse effects. Indeed, for many their structural and functional neuro-imaging. The answer
strengths outweigh identified weaknesses.